Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).

ABSTRACT: Rationale: AIRFLOW-3 was a 1:1 randomized, double-blind, sham-controlled trial of the D'Nerva targeted lung denervation (TLD) system in patients with chronic obstructive pulmonary disease (COPD). Objective: To evaluate the impact of TLD on COPD exacerbations compared with optimal medical treatment. Methods: AIRFLOW-3 patients were symptomatic (COPD Assessment Test score ⩾10) with moderate to very severe airflow obstruction (FEV₁ ≥25% but ⩽80% predicted) and Global Initiative for Chronic Obstructive Lung Disease E status (at least two moderate or one severe exacerbation during the previous 12 mo). The primary endpoint was a comparison of time to the first moderate or severe COPD exacerbation through 12 months between the treatment (TLD plus optimal medical tr

SUBMITTER: Shah PL 

PROVIDER: S-EPMC12700255 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature